Eflornithine
- Generic Name
- Eflornithine
- Brand Names
- Vaniqa
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12F2N2O2
- CAS Number
- 70052-12-9
- Unique Ingredient Identifier
- ZQN1G5V6SR
- Background
Eflornithine is a prescription drug indicated in the treatment of facial hirsutism (excessive hair growth). Eflornithine hydrochloride cream for topical application is intended for use in women suffering from facial hirsutism and is sold by Allergan, Inc. under the brand name Vaniqa. Eflornithine for injection against sleeping sickness was manufactured by Sa...
- Indication
Eflornithine is indicated in the treatment of facial hirsutism (excessive hair growth).
- Associated Conditions
- Meningoencephalitic stage Trypanosoma brucei gambiense infection
- Associated Therapies
- Hair removal therapy
Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
- Conditions
- Interventions
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT00006079
- Locations
- ๐บ๐ธ
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus
- Conditions
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 152
- Registration Number
- NCT00003076
- Locations
- ๐บ๐ธ
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
๐บ๐ธMassachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
๐บ๐ธUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Eflornithine in Treating Patients With Bladder Cancer
- Conditions
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 450
- Registration Number
- NCT00003814
- Locations
- ๐บ๐ธ
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
๐บ๐ธSimmons Cancer Center - Dallas, Dallas, Texas, United States
๐บ๐ธPiedmont Urology PC, Atlanta, Georgia, United States
Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- University of Arizona
- Registration Number
- NCT00021294
- Locations
- ๐บ๐ธ
Arizona Cancer Center, Tucson, Arizona, United States
Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Thomas E. Ahlering
- Target Recruit Count
- 76
- Registration Number
- NCT00006101
- Locations
- ๐บ๐ธ
Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center, Orange, California, United States
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 205
- Registration Number
- NCT00033371
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.